ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Brief Human IL-2 Mutein Therapy Induces Foxp3+ T-Regulatory Cell Expansion and Donor-Specific Allograft Tolerance

L. Wang1, G. J. Babcock2, W. W. Hancock3

1Pathology and Lab Medicine, Childrens Hospital of Philadelphia, Philadelphia, PA, 2Visterra, Inc., Waltham, MA, 3Pathology and Lab Medicine, University of Pennsylvania, Philadelphia, PA

Meeting: 2022 American Transplant Congress

Abstract number: 386

Keywords: Interleukin-2 receptor, T cells, Tolerance

Topic: Basic Science » Basic Science » 10 - Treg/Other Regulatory Cell/Tolerance

Session Information

Session Name: Immunoregulation and Tolerance

Session Type: Rapid Fire Oral Abstract

Date: Monday, June 6, 2022

Session Time: 5:30pm-7:00pm

 Presentation Time: 6:50pm-7:00pm

Location: Hynes Room 302

*Purpose: New therapeutic approaches to the management of transplant recipients are warranted in efforts to improve outcomes.

*Methods: We have engineered a modified human IL-2 protein for preferential binding to the trimeric human IL-2 receptor over the corresponding dimeric IL-2 receptor. This was done by significantly reducing the affinity of IL-2 for CD122 while maintaining native affinity for CD25. In addition, the IL-2 mutein was fused to human IgG1 Fc to promote its extended half-life in vivo. We evaluated the ability of human IL-2 mutein as a tool to enhance Foxp3+ T-regulatory (Treg) cell functions in vitro and in murine allograft recipients.

*Results: In the presence of TGF-β, IL-2 mutein induced Stat5b phosphorylation and promoted inducible murine Treg developmentin vitro by 5-fold or by 8-fold when used in conjunction with a small molecule Cdk8/19 inhibitor that inhibits STAT5b dephosphorylation. Similarly, upon injection in vivo (10 µg s.c. twice/week), IL-2 mutein expanded the murine Foxp3+ Treg population by 4-5-fold. We therefore tested the effects of IL-2 mutein therapy in a fully MHC-mismatched cardiac allograft model (BALB/c->C57BL/6) in which recipients also received low-dose rapamycin (RPM, 0.5 mg/kg/d via Alzet pump for 2 wk post-Tx). Two injections of IL-2 mutein 10 µg s.c. twice in the week pre-Tx, plus low dose RPM for 2 weeks beginning at the time of transplant led to 80% long-term survival (>100 d, p<0.01 vs. RPM alone) but acutely rejected (7-8 d) third-party C3H allografts when challenged at >100 d. In a more clinically relevant protocol, the same dose of IL-2 mutein for 3 weeks post-Tx, in conjunction with low-dose RPM for 2 weeks, resulted in 100% survival for >100 d (p<0.01 vs. RPM alone or IL-2 mutein alone) and again was associated with the rapid (7-8 d) rejection of third-party C3H challenge allografts (p<0.01). Histologic examination of BALB/c allografts harvested at >100 d in mice treated with the IL-2 mutein/low-dose RPM protocol post-Tx showed excellent myocardial preservation, normal blood vessels, and only minor and focal mononuclear cell infiltrates. This contrasted with histologic evidence of ongoing graft rejection and areas of frank necrosis in allografts that maintained ventricular contraction to 100 days post-Tx in mice given 2 weeks of low-dose RPM and twice/week injections of IL-2 mutein for up to 80 days post-Tx.

*Conclusions: We conclude that a brief course of therapy with a selected IL-2 mutein can expand recipient Treg cells, without promoting Teff cell responses, and induce donor-specific allograft tolerance.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Wang L, Babcock GJ, Hancock WW. Brief Human IL-2 Mutein Therapy Induces Foxp3+ T-Regulatory Cell Expansion and Donor-Specific Allograft Tolerance [abstract]. Am J Transplant. 2022; 22 (suppl 3). https://atcmeetingabstracts.com/abstract/brief-human-il-2-mutein-therapy-induces-foxp3-t-regulatory-cell-expansion-and-donor-specific-allograft-tolerance/. Accessed May 30, 2025.

« Back to 2022 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences